After the U.S. economy unexpectedly shed 92,000 jobs in February, investors are seeking shelter from the resulting market volatility. This collection features resilient, non-cyclical companies that historically maintain their value and offer stability during periods of economic deceleration.
Published on March 9
When job losses rise and markets wobble, defensive stocks like these have historically held their ground. This could be exactly the kind of protection your portfolio needs right now.
Many of the companies in this group have long track records of paying dividends, meaning you could earn a regular income stream even while broader markets remain unsettled.
Professional analysts are rotating into defensive sectors as uncertainty around Federal Reserve policy and slowing growth continues — and this group sits right at the centre of that conversation.
After the U.S. economy unexpectedly shed 92,000 jobs in February, markets reacted with sharp uncertainty. This group was built around a simple but powerful idea: when the economy slows down, certain businesses keep ticking along regardless. By focusing on utilities, healthcare, and everyday consumer goods, this collection targets companies that provide the kinds of products and services people simply cannot go without — no matter what the jobs report says.
These are defensive, non-cyclical stocks — meaning their revenues tend to hold up even when the broader economy stumbles. Many of the companies here operate in regulated industries, which adds an extra layer of earnings predictability. Several also have strong dividend histories, meaning they can offer a potential income stream alongside capital stability. This is generally considered a lower-risk style of investing, suited to periods of economic uncertainty.
Every stock in this group was hand-selected by professional analysts specifically because of its recession-resistant qualities. From regulated power providers to government-backed health insurers and everyday household product makers, these companies demonstrate inelastic demand — meaning customers keep buying their products and services even when budgets are tight. They were not chosen at random; they were chosen for their proven ability to preserve value when it matters most.
This basket's total market capitalisation is $1.37T and is heavily weighted toward large-cap stocks that anchor its profile. That weighting suggests a generally stable, lower-volatility profile compared with smaller-cap, higher-growth baskets.
JNJ: $579.34B
UNH: $260.03B
SRE: $60.51B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+7
Here are a few of the assets in this group. Create an account to unlock the full list.
Johnson & Johnson
JNJ
Current Price
$265.58
Johnson & Johnson's diversified healthcare and pharmaceutical products represent essential needs that maintain stable consumer demand during recession...
Johnson & Johnson's diversified healthcare and pharmaceutical products represent essential needs that maintain stable consumer demand during recessions.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 19.13% over the next year.
15 of 17 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+19.13%
